Mexican beaded lizard debate among scientists. However, this venom has been found to contain several enzymes useful for manufacturing drugs in the treatment of diabetes, and research on the pharmacological use of its venom is ongoing. Threatened throughout its range by overcollection and habitat loss, it is a CITES protected species. The Guatemalan beaded lizard ("H. charlesbogerti" ) is one of the rarest lizards in the world, with a wild population of fewer than 200. The beaded lizards have one close living relative, the Gila monster ("H. suspectum"), as well as many extinct relatives in the Helodermatidae, whose genetic history may be traced
Mexican beaded lizard (swelling), weakness, sweating, and a rapid fall in blood pressure. Beaded lizards are immune to the effects of their own venom. Some compounds in its venom have been shown to have pharmacological properties relating to the possible treatment of diabetes, Alzheimer's disease, and even HIV. One compound, a hormone named exendin-3, is marketed by Amylin Pharmaceuticals as the drug exenatide. A study in 1996 revealed that it binds to cell receptors in breast cancer cells and may stop the growth of lung cancer cells. The beaded lizard becomes sexually mature at six to eight years and mates between September and